Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2010-07-12

Clinical Trial Update: Study to Investigate Skin Conditions and Patient Assessment of LAS 41002 in the Treatment of Atopic Eczema [Phase 2]

View source ↗

Summary

Phase 2 study of LAS 41002 for atopic dermatitis has completed. The sponsor is Almirall, S.A.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LAS 41002

Snippet

Sponsor: Almirall, S.A. | Conditions: Atopic Eczema | Phase 2 | Status: COMPLETED